UNSPSC 51372110: Nicomorphine

This classification denotes a morphine derivative and nicotinic acid with the molecular formula C29H25N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y95FRL95FW, chemically known as morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5.alpha.,6.alpha.)-, di-3-pyridinecarboxylate (ester) but generally known as nicomorphine, which bears US NIH Compound Identifier 571623. European Medicines Agency schedules Nicomorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09241MIG.

UNSPSC 51372110 Nicomorphine is a Commodity code that in recent state and local solicitations covers pharmaceutical procurement spanning naloxone, generic multi-source drugs, and over-the-counter products sourced through authorized wholesalers and direct-to-manufacturer relationships. State and local governments use this code to acquire medications and related health products for community health initiatives, pharmacy benefit programs, and public health response capabilities. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances coordinating procurement across multiple jurisdictions. The code sees activity from both individual counties managing acute health needs and statewide or multi-state entities standardizing pharmaceutical supply chains.

Recent activity centers on Florida and Minnesota with secondary involvement from Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023—a response-due date appearing inconsistent with the posting date. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon; evaluation weighting 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on compliance and capability factors. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor market intelligence on direct-to-manufacturer prescription programs and therapeutic pharmacy initiatives before issuing formal solicitation. Contracts typically run two years with renewal options, require E-Verify compliance and drug-free workplace certification, and may impose performance penalties ranging from $200 to $1,500 per violation.